Proangiogenic Features of Mesenchymal Stem Cells and Their Therapeutic Applications

Stem Cells International

Volumn 2016, Issue , 2016, Pages

  Tao, Hongyan ^a,b   Han, Zhibo ^c   Han, Zhong Chao ^c   Li, Zongjin ^a,b  

^a NANKAI UNIVERSITY   (China)

^b NANKAI UNIVERSITY   (China)

^c INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; MICRORNA;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANGIOGENESIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BIOENGINEERING; CELL DIFFERENTIATION; CELL EXPANSION; CELL ISOLATION; CELL REGENERATION; ENDOTHELIUM CELL; EXOSOME; HEART MUSCLE CELL; HUMAN; IMMUNOGENICITY; ISCHEMIC HEART DISEASE; MESENCHYMAL STEM CELL; NONHUMAN; PARACRINE SIGNALING; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 84956555171     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2016/1314709     Document Type: Review

References (110)

1. A. S. Go, D. Mozaffarian, V. L. Roger et al. , Heart disease and stroke statistics-2013 update: a report from the American Heart Association, Circulation, vol. 127, pp. e6-e245, 2013.
2. M. M. Daadi, Z. Li, A. Arac et al. , Molecular and magnetic resonance imaging of human embryonic stem cell-derived neural stem cell grafts in ischemic rat brain,MolecularTherapy, vol. 17, no. 7, pp. 1282-1291, 2009.
3. Z. Li, K. D. Wilson, B. Smith et al. , Functional and transcriptional characterization of human embryonic stem cell-derived endothelial cells for treatment of myocardial infarction, PLoS ONE, vol. 4, no. 12, Article IDe8443, 2009.
4. L. Zimmerlin, T. S. Park, E. T. Zambidis, V. S. Donnenberg, and A. D. Donnenberg, Mesenchymal stem cell secretome and regenerative therapy after cancer, Biochimie, vol. 95, no. 12, pp. 2235-2245, 2013.
5. R. Ross, N. B. Everett, and R. Tyler, Wound healing and collagen formation. VI. The origin of the wound fibroblast studied in parabiosis, The Journal of Cell Biology, vol. 44, no. 3, pp. 645-654, 1970.
6. N. L. Petrakis, M. Davis, and S. P. Lucia, The in vivo differentiation of human leukocytes into histiocytes, fibroblasts and fat cells in subcutaneous diffusion chambers, Blood, vol. 17, pp. 109-118, 1961.
7. A. J. Friedenstein, U. F. Gorskaja, and N. N. Kulagina, Fibroblast precursors in normal and irradiated mouse hematopoietic organs, Experimental Hematology, vol. 4, no. 5, pp. 267-274, 1976.
8. D. Cook and P. Genever, Regulation of mesenchymal stem cell differentiation, Advances in Experimental Medicine and Biology, vol. 786, pp. 213-229, 2013.
9. R. Hass, C. Kasper, S. Bohm, and R. Jacobs, Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC, Cell Communication and Signaling, vol. 9, article 12, 2011.
10. I. Kassis, L. Zangi, R. Rivkin et al. , Isolation of mesenchymal stem cells from G-CSF-mobilized human peripheral blood using fibrin microbeads, BoneMarrow Transplantation, vol. 37, no. 10, pp. 967-976, 2006.
11. J. W. Kuhbier, B. Weyand, C. Radtke, P. M. Vogt, C. Kasper, and K. Reimers, Isolation, characterization, differentiation, and application of adipose-derived stem cells, in Bioreactor Systems for Tissue Engineering II, vol. 123 of Advances in Biochemical Engineering/Biotechnology, pp. 55-105, Springer, Berlin, Germany, 2010.
12. W. Gong, Z. Han, H. Zhao et al. , Banking human umbilical cord-derived mesenchymal stromal cells for clinical use, Cell Transplantation, vol. 21, no. 1, pp. 207-216, 2012.
13. Z. X. Yang,Z. -B. Han, Y. R. Ji et al. , CD106 identifies a subpopulation of mesenchymal stem cells with unique immunomodulatory properties, PLoS ONE, vol. 8, no. 3, Article ID e59354, 2013.
14. R. Sarugaser, L. Hanoun, A. Keating, W. L. Stanford, and J. E. Davies, Human mesenchymal stem cells self-renew and differentiate according to a deterministic hierarchy, PLoS ONE, vol. 4, no. 8, Article ID e6498, 2009.
15. X. Li, J. Bai, X. Ji, R. Li, Y. Xuan, and Y. Wang, Comprehensive characterization of four different populations of human mesenchymal stem cells as regards their immune properties, proliferation and differentiation, International Journal of Molecular Medicine, vol. 34, no. 3, pp. 695-704, 2014.
16. N. F. Huang and S. Li, Mesenchymal stem cells for vascular regeneration, Regenerative Medicine, vol. 3, no. 6, pp. 877-892, 2008.
17. A. R. Williams and J. M. Hare, Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease, Circulation Research, vol. 109, no. 8, pp. 923-940, 2011.
18. V. Aguilera, L. Briceno, H. Contreras et al. , Endothelium trans differentiated from Whartons jelly mesenchymal cells promote tissue regeneration: potential role of soluble pro-angiogenic factors, PLoS ONE, vol. 9, no. 11,Article ID e111025, 2014.
19. F. -J. Lv, R. S. Tuan, K. M. C. Cheung, and V. Y. L. Leung, Concise review: the surface markers and identity of human mesenchymal stem cells, STEM CELLS, vol. 32, no. 6, pp. 1408-1419, 2014.
20. S. Law and S. Chaudhuri, Mesenchymal stem cell and regenerative medicine: regeneration versus immunomodulatory challenges, American Journal of Stem Cells, vol. 2, no. 1, pp. 22-38, 2013.
21. H. Ishimine, N. Yamakawa, M. Sasao et al. , N-Cadherin is a prospective cell surface marker of human mesenchymal stem cells that have high ability for cardiomyocyte differentiation, Biochemical and Biophysical Research Communications, vol. 438, no. 4, pp. 753-759, 2013.
22. M. Das, I. B. Sundell, and P. S. Koka, Adult mesenchymal stem cells and their potency in the cell-based therapy, Journal of Stem Cells, vol. 8, no. 1, pp. 1-16, 2013.
23. L. Chen, Y. Xu, J. Zhao et al. , Conditioned medium from hypoxic bone marrow-derived mesenchymal stem cells enhances wound healing in mice, PLoS ONE, vol. 9, no. 4, Article ID e96161, 2014.
24. Q. Zhao and Z. Li, Angiogenesis, Bio Med Research International, vol. 2015,Article ID 135861, 2 pages, 2015.
25. L. Wang,W. Su,W. Du et al. , Gene andMicroRNA profiling of human induced pluripotent stemcell-derived endothelial cells, Stem Cell Reviews and Reports, vol. 11, pp. 219-227, 2015.
26. F. Dong, J. Harvey, A. Finan, K. Weber, U. Agarwal, and M. S. Penn, Myocardial CXCR4 expression is required for mesenchymal stem cell mediated repair following acutemyocardial infarction, Circulation, vol. 126, no. 3, pp. 314-324, 2012.
27. V. N. S. Garikipati, S. Jadhav, L. Pal, P. Prakash, M. Dikshit, and S. Nityanand, Mesenchymal stem cells from fetal heart attenuate myocardial injury after infarction: an in vivo serial pinhole gated SPECT-CT study in rats, PLoS ONE, vol. 9, no. 6, Article ID e100982, 2014.
28. H. C. Quevedo, K. E. Hatzistergos, B. N. Oskouei et al. , Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity, Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 33, pp. 14022-14027, 2009.
29. V. Karantalis, D. L. DiFede, G. Gerstenblith et al. , Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting: the Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS) trial, Circulation Research, vol. 114, no. 8, pp. 1302-1310, 2014.
30. F. Li, Q. Huang, J. Chen et al. , Apoptotic cells activate the phoenix rising pathway to promote wound healing and tissue regeneration, Science Signaling, vol. 3, no. 110, article ra13, 2010.
31. M. W. Maijenburg, C. Gilissen, S. M. Melief et al. , Nuclear receptors Nur77 andNurr1modulatemesenchymal stromal cell migration, Stem Cells and Development, vol. 21, no. 2, pp. 228-238, 2012.
32. A. A. Mangi, N. Noiseux, D. Kong et al. , Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts, Nature Medicine, vol. 9, no. 9, pp. 1195-1201, 2003.
33. D. Simpson,H. Liu, T. -H. M. Fan, R. Nerem, and S. C. Dudley Jr. , A tissue engineering approach to progenitor cell delivery results in significant cell engraftment and improvedmyocardial remodeling, Stem Cells, vol. 25, no. 9, pp. 2350-2357, 2007.
34. X. -H. Liu, C. -G. Bai, Z. -Y. Xu et al. , Therapeutic potential of angiogenin modified mesenchymal stem cells: angiogenin improves mesenchymal stem cells survival under hypoxia and enhances vasculogenesis inmyocardial infarction,Microvascular Research, vol. 76, no. 1, pp. 23-30, 2008.
35. X. Yao, Y. Liu, J. Gao et al. , Nitric oxide releasing hydrogel enhances the therapeutic efficacy of mesenchymal stemcells for myocardial infarction, Biomaterials, vol. 60, pp. 130-140, 2015.
36. N. He, Y. Xu, W. Du et al. , Extracellular matrix can recover the downregulation of adhesionmolecules after cell detachment and enhance endothelial cell engraftment, Scientific Reports, vol. 5, Article ID 10902, 2015.
37. W. Du, H. Tao, S. Zhao, Z. He, and Z. Li, Translational applications of molecular imaging in cardiovascular disease and stem cell therapy, Biochimie, vol. 116, pp. 43-51, 2015.
38. D. M. Nelson, R. Hashizume, T. Yoshizumi, A. K. Blakney, Z. Ma, andW. R. Wagner, Intramyocardial injection of a synthetic hydrogel with delivery of bFGF and IGF1 in a rat model of ischemic cardiomyopathy, Biomacromolecules, vol. 15, no. 1, pp. 1-11, 2014.
39. D. L. Simpson and S. C. Dudley Jr. , Modulation of human mesenchymal stem cell function in a three-dimensional matrix promotes attenuation of adverse remodelling after myocardial infarction, Journal of Tissue Engineering and Regenerative Medicine, vol. 7, no. 3, pp. 192-202, 2013.
40. H. -J. Wei, C. -H. Chen, W. -Y. Lee et al. , Bioengineered cardiac patch constructed from multilayered mesenchymal stem cells for myocardial repair, Biomaterials, vol. 29, no. 26, pp. 3547-3556, 2008.
41. Z. Raval and D. W. Losordo, Cell therapy of peripheral arterial disease: from experimental findings to clinical trials, Circulation Research, vol. 112, no. 9, pp. 1288-1302, 2013.
42. H. Orbay, Y. Zhang, H. Hong et al. , Positron emission tomography imaging of angiogenesis in a murine hindlimb ischemia model with 64Cu-labeled TRC105, Molecular Pharmaceutics, vol. 10, no. 7, pp. 2749-2756, 2013.
43. Y. Zhang, R. Zhang, Y. Li, G. He, D. Zhang, and F. Zhang, Simvastatin augments the efficacy of therapeutic angiogenesis induced by bone marrow-derived mesenchymal stem cells in a murine model of hindlimb ischemia, Molecular Biology Reports, vol. 39, no. 1, pp. 285-293, 2012.
44. M. Shimamura, H. Nakagami, H. Koriyama, and R. Morishita, Gene therapy and cell-based therapies for therapeutic angiogenesis in peripheral artery disease, Bio Med Research International, vol. 2013, Article ID 186215, 8 pages, 2013.
45. J. D. Ransohoff and J. C. Wu, Imaging stem cell therapy for the treatment of peripheral arterial disease, Current Vascular Pharmacology, vol. 10, no. 3, pp. 361-373, 2012.
46. J. Qin, K. Li, C. Peng et al. , MRI of iron oxide nanoparticlelabeled ADSCs in a model of hindlimb ischemia, Biomaterials, vol. 34, no. 21, pp. 4914-4925, 2013.
47. A. Bronckaers, P. Hilkens, W. Martens et al. , Mesenchymal stem/stromal cells as a pharmacological and therapeutic approach to accelerate angiogenesis, Pharmacology and Therapeutics, vol. 143, no. 2, pp. 181-196, 2014.
48. H. Suzuki and Y. Iso, Clinical application of vascular regenerative therapy for peripheral artery disease, Bio Med Research International, vol. 2013,Article ID 179730, 6 pages, 2013.
49. R. J. Powell, A. J. Comerota, S. A. Berceli et al. , Interimanalysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia, Journal of Vascular Surgery, vol. 54, no. 4, pp. 1032-1041, 2011.
50. D. Lu, B. Chen, Z. Liang et al. , Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial, Diabetes Research and Clinical Practice, vol. 92, no. 1, pp. 26-36, 2011.
51. A. Grochot-Przeczek, J. Dulak, and A. Jozkowicz, Therapeutic angiogenesis for revascularization in peripheral artery disease, Gene, vol. 525, no. 2, pp. 220-228, 2013.
52. Z. Wang, Y. Cui, J. Wang et al. , The effect of thick fibers and large pores of electrospun poly(α-caprolactone) vascular grafts on macrophage polarization and arterial regeneration, Biomaterials, vol. 35, no. 22, pp. 5700-5710, 2014.
53. K. Wang, X. Chen, Y. Pan et al. , Enhanced vascularization in hybrid PCL/gelatin fibrous scaffolds with sustained release of VEGF, Bio Med Research International, vol. 2015, Article ID 865076, 10 pages, 2015.
54. N. LHeureux, S. Paquet, R. Labbe, L. Germain, and F. A. Auger, Acompletely biological tissue-engineered human blood vessel, The FASEB Journal, vol. 12, no. 1, pp. 47-56, 1998.
55. Z. -Y. Zhang, S. -H. Teoh, J. H. P. Hui, N. M. Fisk,M. Choolani, and J. K. Y. Chan, The potential of human fetalmesenchymal stem cells for off-the-shelf bone tissue engineering application, Biomaterials, vol. 33, no. 9, pp. 2656-2672, 2012.
56. J. T. Krawiec, J. S. Weinbaum, C. M. St Croix et al. , A cautionary tale for autologous vascular tissue engineering: impact of human demographics on the ability of adiposederivedmesenchymal stem cells to recruit and differentiate into smoothmuscle cells, Tissue Engineering Part A, vol. 21, no. 3-4, pp. 426-437, 2015.
57. C. K. Hashi, Y. Zhu, G. -Y. Yang et al. , Antithrombogenic property of bone marrow mesenchymal stem cells in nanofibrous vascular grafts, Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 29, pp. 11915-11920, 2007.
58. S. Kanki-Horimoto,H. Horimoto, S. Mieno et al. , Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension, Circulation, vol. 114, no. 1, pp. I181-I185, 2006.
59. S. Mcilhenny, P. Zhang, T. Tulenko et al. , eNOS transfection of adipose-derived stem cells yields bioactive nitric oxide production and improved results in vascular tissue engineering, Journal of Tissue Engineering and Regenerative Medicine, vol. 9, no. 11, pp. 1277-1285, 2015.
60. P. Au, J. Tam, D. Fukumura, and R. K. Jain, Bone marrowderived mesenchymal stem cells facilitate engineering of longlasting functional vasculature, Blood, vol. 111, no. 9, pp. 4551-4558, 2008.
61. F. F. Cunha, L. Martins, P. K. M. Martin, R. S. Stilhano, and S. W. Han, A comparison of the reparative and angiogenic properties of mesenchymal stem cells derived from the bone marrow of BALB/c and C57/BL6 mice in a model of limb ischemia, Stem Cell Research & Therapy, vol. 4, no. 4, article 86, 2013.
62. M. J. Lee, M. Y. Kim, S. C. Heo et al. , Macrophages regulate smooth muscle differentiation of mesenchymal stem cells via a prostaglandin F2α-mediated paracrinemechanism, Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 11, pp. 2733-2740, 2012.
63. W. S. Park, S. C. Heo, E. S. Jeon et al. , Functional expression of smoothmuscle-specific ion channels in TGF-α1-treated human adipose-derived mesenchymal stem cells, American Journal of Physiology-Cell Physiology, vol. 305, no. 4, pp. C377-C391, 2013.
64. L. Bussche and G. R. Van de Walle, Peripheral blood-derived mesenchymal stromal cells promote angiogenesis via paracrine stimulation of vascular endothelial growth factor secretion in the equine model, Stem Cells Translational Medicine, vol. 3, no. 12, pp. 1514-1525, 2014.
65. Y. Xu, L. Liu, L. Zhang et al. , Efficient commitment to functional CD34+ progenitor cells from human bone marrow mesenchymal stem-cell-derived induced pluripotent stem cells, PLoS ONE, vol. 7, no. 4,Article ID e34321, 2012.
66. S. H. Bhang, S. Lee, J. -Y. Shin, T. -J. Lee, H. -K. Jang, and B. -S. Kim, Efficacious and clinically relevant conditioned medium of human adipose-derived stem cells for therapeutic angiogenesis, Molecular Therapy, vol. 22, no. 4, pp. 862-872, 2014.
67. R. A. Boomsma and D. L. Geenen, Mesenchymal stem cells secrete multiple cytokines that promote angiogenesis and have contrasting effects on chemotaxis and apoptosis, PloSONE, vol. 7, no. 4, Article ID e35685, 2012.
68. N. A. Sopko, B. A. Turturice, M. E. Becker et al. , Bone marrow support of the heart in pressure overload is lost with aging, PLoS ONE, vol. 5, no. 12, Article IDe15187, 2010.
69. S. Schlosser, C. Dennler, R. Schweizer et al. , Paracrine effects of mesenchymal stem cells enhance vascular regeneration in ischemic murine skin, Microvascular Research, vol. 83, no. 3, pp. 267-275, 2012.
70. S. M. Watt, F. Gullo, M. van der Garde et al. , The angiogenic properties of mesenchymal stem/stromal cells and their therapeutic potential, British Medical Bulletin, vol. 108, no. 1, pp. 25-53, 2013.
71. H. M. Kwon, S. -M. Hur, K. -Y. Park et al. , Multiple paracrine factors secreted by mesenchymal stem cells contribute to angiogenesis, Vascular Pharmacology, vol. 63, no. 1, pp. 19-28, 2014.
72. S. Botto, D. N. Streblow, V. DeFilippis et al. , IL-6 in human cytomegalovirus secretome promotes angiogenesis and survival of endothelial cells through the stimulation of survivin, Blood, vol. 117, no. 1, pp. 352-361, 2011.
73. B. M. Beckermann, G. Kallifatidis, A. Groth et al. , VEGF expression by mesenchymal stemcells contributes to angiogenesis in pancreatic carcinoma, British Journal of Cancer, vol. 99, no. 4, pp. 622-631, 2008.
74. A. D. Berendsen and B. R. Olsen, How vascular endothelial growth factor-A (VEGF) regulates differentiation of mesenchymal stem cells, The Journal of Histochemistry and Cytochemistry, vol. 62, no. 2, pp. 103-108, 2014.
75. S. Koch, S. Tugues, X. Li, L. Gualandi, and L. Claesson-Welsh, Signal transduction by vascular endothelial growth factor receptors, The Biochemical Journal, vol. 437, no. 2, pp. 169-183, 2011.
76. M. Pasquet, M. Golzio, E. Mery et al. , Hospicells (ascitesderived stromal cells) promote tumorigenicity and angiogenesis, International Journal of Cancer, vol. 126, no. 9, pp. 2090-2101, 2010.
77. M. Zhou, Z. Liu, C. Liu et al. , Tissue engineering of smalldiameter vascular grafts by endothelial progenitor cells seeding heparin-coated decellularized scaffolds, Journal of Bio Medical Materials Research Part B: Applied Biomaterials, vol. 100, no. 1, pp. 111-120, 2012.
78. T. Kaga, H. Kawano, M. Sakaguchi, T. Nakazawa, Y. Taniyama, and R. Morishita, Hepatocyte growth factor stimulated angiogenesis without inflammation: differential actions between hepatocyte growth factor, vascular endothelial growth factor and basic fibroblast growth factor, Vascular Pharmacology, vol. 57, no. 1, pp. 3-9, 2012.
79. H. Shigematsu, K. Yasuda, T. Iwai et al. , Randomized, doubleblind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia, GeneTherapy, vol. 17, no. 9, pp. 1152-1161, 2010.
80. K. -S. Park, Y. -S. Kim, J. -H. Kim et al. , Trophic molecules derived fromhuman mesenchymal stem cells enhance survival, function, and angiogenesis of isolated islets after transplantation, Transplantation, vol. 89, no. 5, pp. 509-517, 2010.
81. L. Timmers, S. K. Lim, I. E. Hoefer et al. , Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction, Stem Cell Research, vol. 6, no. 3, pp. 206-214, 2011.
82. Y. Y. Yeh, H. G. Ozer, A. M. Lehman et al. , Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling, Blood, vol. 125, no. 21, pp. 3297-3305, 2015.
83. C. Emanueli, A. I. Shearn, G. D. Angelini, and S. Sahoo, Exosomes and exosomal miRNAs in cardiovascular protection and repair, Vascular Pharmacology, vol. 71, pp. 24-30, 2015.
84. H. Valadi, K. Ekstrom, A. Bossios, M. Sjostrand, J. J. Lee, and J. O. Lotvall, Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells, Nature Cell Biology, vol. 9, no. 6, pp. 654-659, 2007.
85. A. Waldenstrom and G. Ronquist, Role of exosomes in myocardial remodeling, Circulation Research, vol. 114, no. 2,pp. 315-324, 2014.
86. E. Hergenreider, S. Heydt, K. Treguer et al. , Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs, Nature Cell Biology, vol. 14, no. 3, pp. 249-256, 2012.
87. J. Halkein, S. P. Tabruyn, M. Ricke-Hoch et al. , MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy, The Journal of Clinical Investigation, vol. 123, no. 5, pp. 2143-2154, 2013.
88. T. S. Chen, R. C. Lai, M. M. Lee, A. B. H. Choo, C. N. Lee, and S. K. Lim, Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs,NucleicAcids Research, vol. 38,no. 1, pp. 215-224, 2010.
89. R. C. Lai, F. Arslan, M. M. Lee et al. , Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury, Stem Cell Research, vol. 4, no. 3, pp. 214-222, 2010.
90. J. Oswald, S. Boxberger, B. Jrgensen et al. , Mesenchymal stem cells can be differentiated into endothelial cells in vitro, STEM CELLS, vol. 22, no. 3, pp. 377-384, 2004.
91. R. Thakker and P. Yang, Mesenchymal stem cell therapy for cardiac repair, Current Treatment Options in Cardiovascular Medicine, vol. 16, no. 7, p. 323, 2014.
92. R. -Z. Lin,R. Moreno-Luna,B. Zhou,W. T. Pu, and J. M. Melero-Martin, Equal modulation of endothelial cell function by four distinct tissue-specific mesenchymal stem cells, Angiogenesis, vol. 15, no. 3, pp. 443-455, 2012.
93. S. G. Ball, C. A. Shuttleworth, and C. M. Kielty, Vascular endothelial growth factor can signal through platelet-derived growth factor receptors, Journal of Cell Biology, vol. 177, no. 3, pp. 489-500, 2007.
94. S. A. Gomes, E. B. Rangel, C. Premer et al. , S-nitrosoglutathione reductase (GSNOR) enhances vasculogenesis by mesenchymal stem cells, Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 8, pp. 2834-2839, 2013.
95. M. Wang, Y. Su, H. Sun et al. , Induced endothelial differentiation of cells from a murine embryonic mesenchymal cell line C3H/10T1/2 by angiogenic factors in vitro, Differentiation, vol. 79, no. 1, pp. 21-30, 2010.
96. M. -Y. Chen, P. -C. Lie, Z. -L. Li, and X. Wei, Endothelial differentiation of Whartons jelly-derived mesenchymal stem cells in comparison with bone marrow-derived mesenchymal stem cells, Experimental Hematology, vol. 37, no. 5, pp. 629-640, 2009.
97. Q. -W. He, Y. -P. Xia, S. -C. Chen et al. , Astrocyte-derived sonic hedgehog contributes to angiogenesis in brain microvascular endothelial cells via RhoA/ROCK pathway after oxygenglucose deprivation, Molecular Neurobiology, vol. 47, no. 3, pp. 976-987, 2013.
98. N. Wang, R. Zhang, S. -J. Wang et al. , Vascular endothelial growth factor stimulates endothelial differentiation from mesenchymal stem cells via Rho/myocardin-related transcription factor-a signaling pathway, The International Journal of Biochemistry & Cell Biology, vol. 45, no. 7, pp. 1447-1456, 2013.
99. H. Lin, A. Shabbir, M. Molnar et al. , Adenoviral expression of vascular endothelial growth factor splice variants differentially regulate bone marrow-derived mesenchymal stem cells, Journal of Cellular Physiology, vol. 216, no. 2, pp. 458-468, 2008.
100. D. Wang, J. S. Park, J. S. F. Chu et al. , Proteomic profiling of bone marrow mesenchymal stem cells upon transforming growth factor α1 stimulation,The Journal of Biological Chemistry, vol. 279, no. 42, pp. 43725-43734, 2004.
101. K. Abnaof, N. Mallela, G. Walenda et al. , TGF-α stimulation in human and murine cells reveals commonly affected biological processes and pathways at transcription level, BMC Systems Biology, vol. 8, article 55, 2014.
102. J. -W. Lee, S. -H. Lee, Y. -J. Youn et al. , A randomized, openlabel, multicenter trial for the safety and efficacy of adult mesenchymal stem cells after acute myocardial infarction, Journal of KoreanMedical Science, vol. 29, no. 1, pp. 23-31, 2014.
103. J. M. Hare, J. E. Fishman, G. Gerstenblith et al. , Comparison of allogeneic vs autologous bonemarrow-derivedmesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial,The Journal of theAmericanMedical Association, vol. 308, no. 22, pp. 2369-2379, 2012.
104. J. M. Hare, J. H. Traverse, T. D. Henry et al. , A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction, Journal of the American College of Cardiology, vol. 54, no. 24, pp. 2277-2286, 2009.
105. A. Chullikana, A. S. Majumdar, S. Gottipamula et al. , Randomized, double-blind, phase I/II study of intravenous allogeneic mesenchymal stromal cells in acute myocardial infarction, Cytotherapy, vol. 17, no. 3, pp. 250-261, 2015.
106. L. R. Gao, Y. Chen, N. K. Zhang et al. , Intracoronary infusion of Whartons jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial, BMC Medicine, vol. 13, article 162, 2015.
107. A. W. Heldman, D. L. DiFede, J. E. Fishman et al. , Transendocardialmesenchymal stem cells and mononuclear bonemarrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial, The Journal of the American Medical Association, vol. 311, no. 1, pp. 62-73, 2014.
108. B. Trachtenberg, D. L. Velazquez, A. R. Williams et al. , Rationale and design of the transendocardial injection of autologous human cells (bone marrow or mesenchymal) in chronic ischemic left ventricular dysfunction and heart failure secondary to myocardial infarction (TAC-HFT) trial: a randomized, double-blind, placebo-controlled study of safety and efficacy, American Heart Journal, vol. 161, no. 3, pp. 487-493, 2011.
109. A. B. Mathiasen, A. A. Qayyum, E. Jorgensen et al. , Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial), European Heart Journal, vol. 36, pp. 1744-1753, 2015.
110. A. B. Mathiasen, E. Jorgensen, A. A. Qayyum, M. Haack-Sorensen, A. Ekblond, and J. Kastrup, Rationale and design of the first randomized, double-blind, placebo-controlled trial of intramyocardial injection of autologous bone-marrow derived Mesenchymal Stromal Cells in chronic ischemic Heart Failure (MSC-HF Trial), American Heart Journal, vol. 164, no. 3, pp. 285-291, 2012.